In the study, an SSO (brand name Nusinersen), specifically targeted SREs, was used to prevent the skipping of SMN2 (survival of motor neuron 2) exon 7, increasing the total amount of intact SMN2, and greatly relieved spinal muscular atrophy. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.